Sabato 27 ottobre 2012 - Pacini Editore

PoStER
Fig. 1. ductal invasive Breast Cancer with strong Her-2 positivity
(score 3+) (40X).
Fig. 2. fluorescence in Situ Hybridization. Her-2 non-amplified ductal
invasive Breast Cancer with Cep17 disorder (Cep17 ≥ 3) (100X).
but also the recent study by Bartlett et al. (Lancet Oncol
2010;11:266–74) indicate that large prospective clinical trials are
necessary to validate whether patients showing increased CEP17
indeed show a better response to HER2-targeted therapies and
anthracyclines, also in the absence of HER2 amplification.
references
1 Shah SS, Wang Y, Tull J, et al.”. Diagn Mol Pathol 2009;18:30-3.
2 Bose S, Mohammed M, Shintaku P, et al. Her-2/neu gene amplification
in low to moderately expressing breast cancers: possible role of
chromosome 17/Her-2/neu polysomy. Breast J 2001;7:337-44.
HEr-2/neu overexpression as potential prognostic
factor in small size breast carcinoma (pT1n0M0)
S. Petroni1 , M. Asselti1 , A. Bruno2 , F. Palma1 , A.L. Marzano1 ,
F. Giotta2 , G. Simone1 1 2 Anatomic Pathology Unit, Medical Oncology Department; National
Cancer Research Centre, Istituto Tumori “Giovanni Paolo II”, Bari, Italy
Background. Patients with primary breast cancer pT1a-bN0M0,
have generally a favourable prognosis. However relapse occurred
up to 25% of cases so it is necessary to identify bio-pathological
and bio-molecular parameters in order to administer target
therapy 1 2 . The aim of this retrospective study was to identify
prognostic factors and predictive factors associated with clinical
outcome.
399
Methods. 292 women (median age: 61 years) with pT1N0M0
breast cancer observed from 2004 until 2010, entered in the study.
187/292 tumors (64%) were pT1c, whereas 105 (36%) were
pT1a-b. ER, PgR, Ki-67 status were evaluated using immunohistochemistry
(IHC); HER-2/neu protein expression was investigated
by IHC (HercepTest, DAKO), HER-2/neu gene status was
assessed by FISH and scored according to FDA guidelines 3 .
Fig. 1. Cdi, ER positive (40x).
Fig. 2. Cdi, pgR positive (40x).
Fig. 3. Ki-67 ≥ 20%, Cdi (20x).